

# Roy A Jensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9302713/publications.pdf>

Version: 2024-02-01

101  
papers

7,248  
citations

76196

40  
h-index

60497

81  
g-index

103  
all docs

103  
docs citations

103  
times ranked

7841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. <i>Nature Genetics</i> , 1995, 9, 444-450.	9.4	552
2	The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. <i>Oncogene</i> , 2000, 19, 968-988.	2.6	455
3	Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. <i>Cancer</i> , 1995, 76, 1197-1200.	2.0	409
4	Growth retardation and tumour inhibition by BRCA1. <i>Nature Genetics</i> , 1996, 12, 298-302.	9.4	359
5	Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. <i>Lancet</i> , The, 2003, 361, 125-129.	6.3	321
6	Proteomics in Diagnostic Pathology. <i>American Journal of Pathology</i> , 2004, 165, 1057-1068.	1.9	257
7	Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. , 1996, 78, 258-266.		233
8	Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. <i>Seminars in Cancer Biology</i> , 2016, 40-41, 192-208.	4.3	217
9	Benign Transport of Breast Epithelium Into Axillary Lymph Nodes After Biopsy. <i>American Journal of Clinical Pathology</i> , 2000, 113, 259-265.	0.4	204
10	BRCA1 Expression Restores Radiation Resistance in BRCA1-defective Cancer Cells through Enhancement of Transcription-coupled DNA Repair. <i>Journal of Biological Chemistry</i> , 1999, 274, 18808-18812.	1.6	203
11	BRCA1 is secreted and exhibits properties of a granin. <i>Nature Genetics</i> , 1996, 12, 303-308.	9.4	198
12	Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. <i>Cancer</i> , 1994, 73, 118-124.	2.0	171
13	Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. , 1999, 85, 2170-2182.		170
14	Invasive breast cancer risk in women with sclerosing adenosis. <i>Cancer</i> , 1989, 64, 1977-1983.	2.0	169
15	Core Biopsy of the Breast With Atypical Ductal Hyperplasia. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1017-1021.	2.1	153
16	Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2002, 13, 1292-1297.	1.2	153
17	A Human Breast Cell Model of Preinvasive to Invasive Transition. <i>Cancer Research</i> , 2008, 68, 1378-1387.	0.4	145
18	Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 707-714.	1.1	144

#	ARTICLE	IF	CITATIONS
19	Metaplastic Spindle Cell Breast Tumors Arising within Papillomas, Complex Sclerosing Lesions, and Nipple Adenomas. <i>Modern Pathology</i> , 2003, 16, 893-901.	2.9	129
20	BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 13650-13655.	3.3	121
21	Transgenic Mice Expressing a Dominant-Negative Mutant Type II Transforming Growth Factor- $\beta$ Receptor Exhibit Impaired Mammary Development and Enhanced Mammary Tumor Formation. <i>American Journal of Pathology</i> , 2003, 163, 1539-1549.	1.9	120
22	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	3.2	108
23	A training-testing approach to the molecular classification of resected non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4695-704.	3.2	102
24	Caveolin Is an Inhibitor of Platelet-Derived Growth Factor Receptor Signaling. <i>Experimental Cell Research</i> , 1999, 247, 380-388.	1.2	101
25	P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. <i>Cancer</i> , 1994, 73, 2147-2156.	2.0	98
26	Characterization of Human Brain S100 Protein Fraction: Amino Acid Sequence of S100 $\beta$ . <i>Journal of Neurochemistry</i> , 1985, 45, 700-705.	2.1	92
27	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
28	Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression. <i>Cell Death and Disease</i> , 2018, 9, 326.	2.7	78
29	No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. <i>Cancer</i> , 2001, 92, 30-36.	2.0	76
30	When the good go bad: Mutant NPM1 in acute myeloid leukemia. <i>Blood Reviews</i> , 2018, 32, 167-183.	2.8	73
31	Estrogen replacement therapy in women with a history of proliferative breast disease. , 1999, 85, 1277-1283.		69
32	High-Mobility Group (HMG) Protein HMG-1 and TATA-Binding Protein-Associated Factor TAF <sub>30</sub> Affect Estrogen Receptor-Mediated Transcriptional Activation. <i>Molecular Endocrinology</i> , 1997, 11, 1009-1019.	3.7	66
33	RNA Binding Protein CUGBP2/CELF2 Mediates Curcumin-Induced Mitotic Catastrophe of Pancreatic Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e16958.	1.1	65
34	Routinely available indicators of prognosis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998, 51, 195-208.	1.1	62
35	Honokiol inhibits melanoma stem cells by targeting notch signaling. <i>Molecular Carcinogenesis</i> , 2015, 54, 1710-1721.	1.3	62
36	Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. <i>Carcinogenesis</i> , 2014, 35, 795-806.	1.3	61

#	ARTICLE	IF	CITATIONS
37	Genetically engineered mouse models of mammary intraepithelial neoplasia. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2000, 5, 421-437.	1.0	59
38	Reactive Spindle Cell Nodules of the Breast After Core Biopsy or Fine-Needle Aspiration. <i>American Journal of Clinical Pathology</i> , 2000, 113, 288-294.	0.4	59
39	Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. <i>Oncotarget</i> , 2016, 7, 3217-3232.	0.8	59
40	Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage Iâ€“III Triple-negative Breast Cancer (NeoSTOP). <i>Clinical Cancer Research</i> , 2021, 27, 975-982.	3.2	51
41	The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice. <i>Gastroenterology</i> , 2019, 157, 1646-1659.e11.	0.6	50
42	The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. <i>Journal of Cancer Therapeutics &amp; Research</i> , 2014, 3, 2.	1.2	48
43	Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. <i>Human Pathology</i> , 1999, 30, 1040-1049.	1.1	45
44	Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway. <i>Scientific Reports</i> , 2020, 10, 1290.	1.6	44
45	Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response. <i>Cancer Research</i> , 2019, 79, 1681-1695.	0.4	40
46	Evaluation and management of high risk and premalignant lesions of the breast. <i>World Journal of Surgery</i> , 1994, 18, 32-38.	0.8	36
47	Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy. <i>Cancer</i> , 2006, 107, 1227-1233.	2.0	36
48	Ductal Carcinoma In Situ of the Breast. <i>American Journal of Surgical Pathology</i> , 2003, 27, 828-831.	2.1	33
49	Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. <i>Translational Research</i> , 2012, 160, 178-197.	2.2	32
50	When and to What End Do Pathologists Agree?. <i>Journal of the National Cancer Institute</i> , 1998, 90, 88-89.	3.0	30
51	Mitochondrial Haplotype Alters Mammary Cancer Tumorigenicity and Metastasis in an Oncogenic Driverâ€“Dependent Manner. <i>Cancer Research</i> , 2017, 77, 6941-6949.	0.4	28
52	High-Mobility Group (HMG) Protein HMG-1 and TATA-Binding Protein-Associated Factor TAFII30 Affect Estrogen Receptor-Mediated Transcriptional Activation. , 0, .		27
53	Characterization of baculovirus-expressed human .alpha. and .beta. platelet-derived growth factor receptors. <i>Biochemistry</i> , 1992, 31, 10887-10892.	1.2	26
54	Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion. <i>Human Pathology</i> , 2001, 32, 785-790.	1.1	26

#	ARTICLE	IF	CITATIONS
55	Pleotropic role of RNA binding protein CELF2 in autophagy induction. <i>Molecular Carcinogenesis</i> , 2019, 58, 1400-1409.	1.3	26
56	Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway. <i>American Journal of Surgery</i> , 2014, 208, 995-1002.	0.9	23
57	Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. <i>Gastroenterology</i> , 2020, 158, 1433-1449.e27.	0.6	23
58	p53: The promising story continues to unfold. <i>Human Pathology</i> , 1993, 24, 455-456.	1.1	21
59	Reply to "p53 and secreted tumour suppressors". <i>Nature Genetics</i> , 1996, 13, 269-272.	9.4	20
60	Structure and function analysis of the human myeloid cell nuclear differentiation antigen promoter: Evidence for the role of Sp1 and not of c-Myb or PU.1 in myelomonocytic lineage-specific expression. <i>Journal of Cellular Biochemistry</i> , 1997, 65, 231-244.	1.2	20
61	Monoclonality in fibroadenomas with complex histology and phyllodal features. <i>Breast Cancer Research and Treatment</i> , 1998, 50, 185-191.	1.1	20
62	Diagnostic criteria and cancer risk of proliferative breast lesions. <i>Journal of Cellular Biochemistry</i> , 1993, 53, 59-64.	1.2	19
63	3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2146-2156.	1.9	19
64	Celastrol and Triptolide Suppress Stemness in Triple Negative Breast Cancer: Notch as a Therapeutic Target for Stem Cells. <i>Biomedicines</i> , 2021, 9, 482.	1.4	19
65	Historical and epidemiologic background of human premalignant breast disease. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2000, 5, 341-349.	1.0	18
66	Preclinical Pharmacokinetics of Fosclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 148-159.	1.3	17
67	BRCA1 "No Matter How You Splice It. <i>Cancer Research</i> , 2019, 79, 2091-2098.	0.4	16
68	OVARIAN CANCER GENE THERAPY. <i>Hematology/Oncology Clinics of North America</i> , 1998, 12, 539-552.	0.9	14
69	Lobulocentricity of Breast Hypersecretory Hyperplasia With Cytologic Atypia. <i>American Journal of Clinical Pathology</i> , 2004, 122, 714-720.	0.4	14
70	An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression. <i>Cancer Gene Therapy</i> , 2003, 10, 559-570.	2.2	13
71	Effects of BRCA1 Transgene Expression on Murine Mammary Gland Development and Mutagen-Induced Mammary Neoplasia. <i>International Journal of Biological Sciences</i> , 2007, 3, 281-291.	2.6	13
72	Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. <i>Leukemia</i> , 2019, 33, 1675-1686.	3.3	12

#	ARTICLE	IF	CITATIONS
73	Essential Components of Cancer Education. <i>Cancer Research</i> , 2015, 75, 5202-5205.	0.4	10
74	Relevant Word Order Vectorization for Improved Natural Language Processing in Electronic Health Records. <i>Scientific Reports</i> , 2019, 9, 9253.	1.6	9
75	Honokiol Affects Stem Cell Viability by Suppressing Oncogenic YAP1 Function to Inhibit Colon Tumorigenesis. <i>Cells</i> , 2021, 10, 1607.	1.8	8
76	Gene Therapy for Breast and Ovarian Cancer with BRCA1. <i>Breast Disease</i> , 1998, 10, 89-98.	0.4	7
77	Targeted Therapy for EBV-Associated B-cell Neoplasms. <i>Molecular Cancer Research</i> , 2019, 17, 839-844.	1.5	7
78	Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 151, 33-80.	0.9	6
79	Mitochondrial polymorphisms contribute to aging phenotypes in MNX mouse models. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 633-642.	2.7	6
80	Foscicliprox suppresses growth of high-grade urothelial cancer by targeting the $\beta$ -secretase complex. <i>Cell Death and Disease</i> , 2021, 12, 562.	2.7	6
81	Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes. <i>Cancer Gene Therapy</i> , 2001, 8, 231-239.	2.2	5
82	Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. <i>Molecular Cancer Research</i> , 2021, 19, 913-920.	1.5	5
83	Prostatic adenocarcinoma with glomeruloid features. <i>Human Pathology</i> , 1999, 30, 111-112.	1.1	3
84	CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 14.	2.8	3
85	OPTIK: a database for understanding catchment areas to guide mobilization of cancer center assets. <i>Database: the Journal of Biological Databases and Curation</i> , 2020, 2020, .	1.4	3
86	[35] Analysis of cancer gene functions through gene inhibition with antisense oligonucleotides. <i>Methods in Enzymology</i> , 2000, 314, 499-506.	0.4	2
87	Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	2
88	Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.	2.3	2
89	Sclerosing Adenosis and the Risk of Invasive Breast Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 1993, 2, 25-34.	0.6	1
90	RAP-PCR Using RNA from Tissue Microdissection. , 1997, 85, 277-284.		1

#	ARTICLE	IF	CITATIONS
91	Atypical Ductal Hyperplasia on Core Biopsy. , 2003, 8, 245-248.		1
92	Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of foscicliprox (CPX-POM) in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 518-518.	0.8	1
93	Atypical Ductal Hyperplasia on Core Biopsy. , 2003, 8, 245-248.		0
94	Utilization of Technology to Improve Efficiency in Investigational Drug Management Processes. Journal of Pharmacy Technology, 2020, 36, 84-90.	0.5	0
95	Role of Bitter Taste Receptor TAS2R38 In Colorectal Cancer. FASEB Journal, 2021, 35, .	0.2	0
96	Evaluating the role of RNA binding protein CELF2 in modulating immune cells in colitis. FASEB Journal, 2021, 35, .	0.2	0
97	Routinely available indicators of prognosis in breast cancer. , 1998, , 3-16.		0
98	Benign Breast Lesions. , 1999, , 331-346.		0
99	Targeting the Prolactin Receptor Signaling Using an Antipsychotic Drug to Suppress Pancreatic Cancer. FASEB Journal, 2018, 32, 610.3.	0.2	0
100	Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells. Blood, 2019, 134, 2865-2865.	0.6	0
101	RNA Binding Protein RBM3 Modulates Novel LncRNAs to Increase Tumor Progression in Colon Cancer Cells. FASEB Journal, 2020, 34, 1-1.	0.2	0